Scientists Identify Immune Cells That Attack the Pancreas in Type 1 Diabetes

Type 1 diabetes develops when the immune system mistakenly attacks insulin-producing beta cells in the pancreas. For years, researchers have known this autoimmune process is involved, but they haven't fully understood which specific immune cells are responsible or what they are attacking.

A new study published in 2026 takes a major step toward answering these questions. Scientists used an unbiased approach to search through immune cell data from people with type 1 diabetes and healthy controls, without assuming in advance what they would find. This led them to discover 264 T-cell receptors—the molecules that help immune cells recognize threats—that are strongly linked to type 1 diabetes.

The research provides multiple lines of evidence that these T-cell receptors are genuinely involved in type 1 diabetes, not just coincidental findings. The receptors cluster together in patterns connected to HLA-DQ8 and HLA-DQ2.5, genetic risk factors known to increase T1D susceptibility. They are found almost exclusively in people with type 1 diabetes and largely absent in matched controls.

Perhaps most importantly, these immune cells appear in the blood before autoantibodies—the antibodies that researchers traditionally use to detect early T1D—suggesting they could be an even earlier warning sign. When researchers looked at tissue affected by diabetes, they found these receptors displayed the characteristics of active, disease-causing immune cells. In contrast, on the rare occasions when researchers found these same receptors in healthy people, they more often had a regulatory character—suggesting the immune system was keeping them in check.

Knowing which immune cells are involved is only half the puzzle. Researchers also needed to identify exactly what these cells are attacking. Using laboratory techniques to reverse-engineer the T-cell receptors, scientists systematically tested them against potential antigenic targets.

The results converged on a specific target: hybrid insulin peptides (HIPs)—molecular fragments created when insulin is processed in the body. These are not intact insulin molecules, but rather pieces formed during natural insulin breakdown. The identified T-cell receptors preferentially recognized these hybrid forms over native insulin peptides, and remained specific when tested against a wide range of other proteins in the body.

This discovery bridges a major gap in type 1 diabetes science. By connecting specific immune receptors to concrete antigenic targets, the work provides a molecular roadmap of the autoimmune attack. It shows that the immune response in type 1 diabetes is not random but focused on particular insulin-derived fragments.

The findings open new avenues for research. Understanding how and why immune cells attack hybrid insulin peptides could eventually help scientists develop strategies to prevent the autoimmune response or identify people at highest risk long before their diagnosis. The presence of these T-cell receptors in blood, appearing even before traditional autoantibody tests turn positive, suggests they could become part of a new screening approach for people at risk of developing type 1 diabetes.

Source: Research square. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.